News from immunocellular therapeutics, ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2015, 16:01 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the second...

Jul 06, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo

ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the establishment of an agreement with Novella...

Jun 29, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Present at Cantor Fitsgerald Inaugural Healthcare Conference on July 8th

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of...

Jun 22, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio...

Jun 15, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced the selection of PCT, LLC, a subsidiary of Caladrius Biosciences,...

May 19, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 28th

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of...

May 11, 2015, 16:01 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Announces First Quarter 2015 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter 2015.  "During...

May 11, 2015, 08:40 ET
View investor presentations 24/7 at www.virtualinvestorconferences.com.

ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation...

May 05, 2015, 08:30 ET
View investor presentations 24/7 at www.virtualinvestorconferences.com.

ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7

Company invites individual and institutional investors to attend interactive real-time virtual roadshow  ImmunoCellular Therapeutics,...

Apr 30, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Report First Quarter 2015 Financial Results on May 11, 2015; Conference Call and Webcast to be Held on May 12, 2015

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the first...

Mar 19, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the establishment of an agreement with PharmaCell B.V....

Mar 09, 2015, 16:01 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and year ended...

Mar 03, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo

ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of...

Mar 02, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report financial results for the year ended...

Feb 18, 2015, 16:05 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Strengthens Executive Management Team with Appointment of Dr. Steven Swanson to Lead Stem-to-T-Cell Program

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the appointment of Steven J. Swanson, PhD, as...

Feb 12, 2015, 08:06 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an...

Jan 28, 2015, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will...

Dec 17, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo

ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a...

Dec 01, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program

 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the European Medicines Agency (EMA) has provided...

Nov 14, 2014, 06:00 ET
ImmunoCellular Therapeutics Logo.

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announces the presentation today of updated efficacy data from the phase II...